TG Therapeutics Inc expected to post earnings of 8 cents a share - Earnings Preview

TG Therapeutics

28/02/2025 14:12

TG Therapeutics Inc TGTX.OQ TGTX.O is expected to show a rise in quarterly revenue when it reports  results on March 3 for the period ending December 31 2024

The Morrisville North Carolina-based  company is expected to report a 127.3% increase in revenue to $99.954 million from $43.97 million a year ago, according to the mean estimate from 6 analysts, based on LSEG data.

​LSEG's mean analyst estimate for TG Therapeutics Inc is for earnings of 8 cents per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy," no "hold" and 1 "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for TG Therapeutics Inc is $43.00​, above​ its last closing price of $28.53. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Sep. 30 2024
0.04
0.03
0.02
Missed
-32.2
Jun. 30 2024
-0.05
-0.05
0.04
Beat
187.5
Mar. 31 2024
-0.02
-0.04
-0.07
Missed
-96​
Dec. 31 2023
-0.12
-0.10
-0.10
Met
4.1
​​Sep. 30 2023
0.05
0.12
0.73
Beat
530.9
Jun. 30 2023
-0.24
-0.25
-0.34
Missed
-36.7​
Mar. 31 2023
-0.38
-0.37
-0.28
Beat
23.7
Dec. 31 2022
-0.28
-0.26
-0.39
Missed
-50

This summary was machine generated February 28 at 14:12 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)